Nathaniel Weygant - Search Results

Year	Number of Results
2012	1
2013	3
2014	5
2015	7
2016	3
2017	1
2018	2
2019	4
2020	11
2021	6
2022	5
2023	3
2024	0

1

Applications of organoid technology to brain tumors.

Wen J, Liu F, Cheng Q, Weygant N, Liang X, Fan F, Li C, Zhang L, Liu Z. Wen J, et al. Among authors: weygant n. CNS Neurosci Ther. 2023 Oct;29(10):2725-2743. doi: 10.1111/cns.14272. Epub 2023 May 29. CNS Neurosci Ther. 2023. PMID: 37248629 Free PMC article. Review.

2

Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation.

Wang Z, Su G, Dai Z, Meng M, Zhang H, Fan F, Liu Z, Zhang L, Weygant N, He F, Fang N, Zhang L, Cheng Q. Wang Z, et al. Among authors: weygant n. Cell Prolif. 2021 Mar;54(3):e12988. doi: 10.1111/cpr.12988. Epub 2021 Jan 13. Cell Prolif. 2021. PMID: 33442944 Free PMC article.

3

Role of the Microenvironment in Gastrointestinal Tumors.

Weygant N, Ge Y, Westphalen CB, Ma WW, Vega KJ. Weygant N, et al. J Oncol. 2019 Dec 11;2019:2153413. doi: 10.1155/2019/2153413. eCollection 2019. J Oncol. 2019. PMID: 31885570 Free PMC article. No abstract available.

4

Role of DCLK1 in oncogenic signaling (Review).

Lu Q, Feng H, Chen H, Weygant N, Du J, Yan Z, Cao Z. Lu Q, et al. Among authors: weygant n. Int J Oncol. 2022 Nov;61(5):137. doi: 10.3892/ijo.2022.5427. Epub 2022 Sep 23. Int J Oncol. 2022. PMID: 36148883 Review.

5

DCLK1 and tuft cells: Immune-related functions and implications for cancer immunotherapy.

Ding L, Weygant N, Ding C, Lai Y, Li H. Ding L, et al. Among authors: weygant n. Crit Rev Oncol Hematol. 2023 Nov;191:104118. doi: 10.1016/j.critrevonc.2023.104118. Epub 2023 Sep 2. Crit Rev Oncol Hematol. 2023. PMID: 37660932 Review.

6

Tuft cells: an emerging therapeutic target for pancreatitis and pancreatic cancer?

Yang Y, Ding L, Cao Z, Qu D, Weygant N. Yang Y, et al. Among authors: weygant n. Expert Opin Ther Targets. 2020 Dec;24(12):1183-1186. doi: 10.1080/14728222.2020.1841168. Epub 2020 Nov 12. Expert Opin Ther Targets. 2020. PMID: 33176507 No abstract available.

7

Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-derived Organoids.

Ding L, Yang Y, Lu Q, Cao Z, Weygant N. Ding L, et al. Among authors: weygant n. Curr Cancer Drug Targets. 2022;22(3):195-208. doi: 10.2174/1568009622666220117124546. Curr Cancer Drug Targets. 2022. PMID: 35078398 Review.

8

Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers.

Ge Y, Westphalen CB, Ma WW, Vega KJ, Weygant N. Ge Y, et al. Among authors: weygant n. J Oncol. 2019 Oct 31;2019:4835318. doi: 10.1155/2019/4835318. eCollection 2019. J Oncol. 2019. PMID: 32082375 Free PMC article. Review.

9

Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.

Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Cao Z, et al. Among authors: weygant n. Cancers (Basel). 2020 Dec 17;12(12):3801. doi: 10.3390/cancers12123801. Cancers (Basel). 2020. PMID: 33348546 Free PMC article. Review.

10

Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.

Liang Z, Zhang E, Duan L, Weygant N, An G, Hu B, Yao J. Liang Z, et al. Among authors: weygant n. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211068960. doi: 10.1177/15330338211068960. Technol Cancer Res Treat. 2022. PMID: 35179409 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

49 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year